Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)
Condition: Urinary Bladder Cancer, Muscle-invasive Interventions: Drug: Pembrolizumab; Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]) Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials